人工智能驱动的前列腺癌多学科团队推荐精简:英国三级NHS中心研究
本研究评估基于规则的人工智能临床决策支持系统PROSAIC-DS在前列腺癌MDT路径中识别可减少讨论患者的效果。两阶段分别回顾性分析287例和前瞻性分析416例患者,与专家小组 ground truth 比较一致性。结果显示PROSAIC-DS一致性达92%和85.6%,使33.8%患者绕过MDT讨论。
要点
- PROSAIC-DS与临床推荐一致性达92%(第一阶段)和85.6%(第二阶段)。
- 机器学习决策树识别93例可精简管理患者,该亚组一致性97.8%。
- 33.8%患者可绕过MDT讨论且治疗一致性高。
核心结论
- PROSAIC-DS融入前列腺癌MDT路径可使33.8%患者绕过MDT讨论且治疗一致性高。
- AI解决方案有望改善肿瘤临床工作流程并应对MDT工作负荷挑战。
研究设计与样本
- 两阶段研究:第一阶段回顾性一致性分析287例国王学院医院前列腺MDT转诊患者(2年)。
- 第二阶段前瞻性分析416例盖伊医院患者(另2年),其中355例可评估。
- 临床治疗推荐由泌尿外科和肿瘤科医生小组独立审查建立ground truth。
主要发现
- 第一阶段临床医生推荐与PROSAIC-DS总体一致性92%(95%CI 88.1-94.7%),历史MDT输出仅53%(95%CI 47-59%)(P<0.01)。
- 第二阶段PROSAIC-DS与MDT推荐一致性85.6%(95%CI 81.6-88.9%)(P<0.01)。
- 机器学习决策树识别93例精简管理患者,该亚组一致性97.8%(P<0.01)。
临床怎么用
- PROSAIC-DS可辅助识别符合标准治疗指南、可减少MDT讨论的前列腺癌患者。
- 该系统有望精简MDT流程,降低工作负荷,同时保持高治疗一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the effectiveness of a rules-based artificial intelligence (AI) clinical decision support system (CDSS) called the PROState AI Cancer-Decision Support (PROSAIC-DS) in streamlining the prostate cancer multidisciplinary team (MDT) pathway by identifying patients meeting standard of care (SoC) guidelines for reduced discussion in MDT meetings. SUBJECTS/PATIENTS AND METHODS: This study consisted of two phases. Phase one involved a retrospective concordance analysis of 287 patients referred to the prostate MDT at King's College Hospital over a 2-year period. In phase two, a prospective analysis included 416 patients from Guy's Hospital over another 2-year period. Clinical treatment recommendations were independently reviewed by a panel of urologists and oncologists to establish a 'ground truth.' Concordance between the medical recommendations and those generated by the PROSAIC-DS was assessed. RESULTS: In phase one, the overall concordance between the clinicians' recommendations and the PROSAIC-DS was 92% (95% confidence interval [CI] 88.1-94.7%), compared to just 53% (95% CI 47-59%) with historic MDT outputs (P < 0.01). In phase two, the PROSAIC-DS achieved an 85.6% concordance (95% CI 81.6-88.9%) with the MDT recommendations for 355 evaluable cases (P < 0.01). Notably, using a machine learning-derived decision tree enabled the identification of 93 patients for streamlined management, demonstrating a 97.8% concordance in this subgroup (P < 0.01). CONCLUSION: The implementation of the PROSAIC-DS into the prostate cancer MDT pathway allowed 33.8% of patients to bypass MDT discussions with high treatment concordance. This study showcases the potential for AI-based solutions to improve clinical workflow and patient management in oncology, thus addressing the workload challenges faced by MDTs.
引用
- Khattak A, Ruta D, Patkar V, et al. Artificial intelligence-driven streamlining of prostate cancer multidisciplinary team recommendations in a tertiary NHS centre in the UK. BJU Int. 2025. PMID: 40590412. doi:10.1111/bju.16845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。